TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis

Hepatology

Volumn 57, Issue 4, 2013, Pages 1416-1425

  Matsubara, Tokuhiro ^a   Kanto, Tatsuya ^a   Kuroda, Shoko ^a   Yoshio, Sachiyo ^a   Higashitani, Koyo ^a   Kakita, Naruyasu ^a   Miyazaki, Masanori ^a   Sakakibara, Mitsuru ^b   Hiramatsu, Naoki ^a   Kasahara, Akinori ^a   Tomimaru, Yoshito ^c   Tomokuni, Akira ^c   Nagano, Hiroaki ^c   Hayashi, Norio ^d   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANGIOPOIETIN RECEPTOR; ANGIOTENSIN II; CD14 ANTIGEN; CD16 ANTIGEN; DECARBOXYPROTHROMBIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; WESTERN BLOTTING;

AGED; ALPHA-FETOPROTEINS; ANGIOPOIETIN-2; ANTIGENS, CD14; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN PRECURSORS; PROTHROMBIN; RECEPTOR, TIE-2; RECEPTORS, IGG; TUMOR MARKERS, BIOLOGICAL;

EID: 84876147785     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25965     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
4. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-631.
5. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. HEPATOLOGY 1998; 27: 1554-1562.
6. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011; 31: 146-162.
7. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103: 588-598.
8. Kuboki S, Shimizu H, Mitsuhashi N, Kusashio K, Kimura F, Yoshidome H, et al. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: e157-164.
9. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Hisamoto T, Yoshida Y, et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 2010; 23: 1647-1654.
10. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100: 1385-1392.
11. Tamesa T, Iizuka N, Mori N, Okada T, Takemoto N, Tangoku A, et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1122-1126.
12. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19: 91-99.
13. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-226.
14. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-7411.
15. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-5285.
16. Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res 2010; 40( Suppl 1): 2-144.
17. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20: 1775-1785.
18. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70: 5270-5280.
19. Mund JA, Case J. The ontogeny of endothelial progenitor cells through flow cytometry. Curr Opin Hematol 2011; 18: 166-170.
20. Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, Zhou X, et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 2009; 10: 403.
21. Koch S, Kucharzik T, Heidemann J, Nusrat A, Luegering A. Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease. Clin Exp Immunol 2010; 161: 332-341.
22. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010; 5: e11049.
23. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1457-1467.
24. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010; 70: 10150-10160.
25. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007; 33: 208-212.
26. Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C. Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int J Dev Biol 2011; 55: 527-534.
27. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, et al. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94: 175-180.
28. Talaat RM. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity. Viral Immunol 2010; 23: 151-157.
29. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707-2716.